Journal
INFLAMMOPHARMACOLOGY
Volume 29, Issue 5, Pages 1291-1306Publisher
SPRINGER BASEL AG
DOI: 10.1007/s10787-021-00863-2
Keywords
Autoimmune disease; Bortezomib; Proteasome inhibitor; Proteasome; NF-kB; ER homeostasis
Categories
Ask authors/readers for more resources
Autoimmune diseases are conditions where the immune system cannot distinguish self from non-self, leading to tissue injury. The proteasome inhibitor bortezomib has shown effectiveness in treating patients with ADs resistant to conventional therapies.
Autoimmune diseases (ADs) are conditions in which the immune system cannot distinguish self from non-self and, as a result, tissue injury occurs primarily due to the action of various inflammatory mediators. Different immunosuppressive agents are used for the treatment of patients with ADs, but some clinical cases develop resistance to currently available therapies. The proteasome inhibitor bortezomib (BTZ) is an approved agent for first-line therapy of people with multiple myeloma. BTZ has been shown to improve the symptoms of different ADs in animal models and ameliorated symptoms in patients with systemic lupus erythematous, rheumatoid arthritis, myasthenia gravis, neuromyelitis optica spectrum disorder, Chronic inflammatory demyelinating polyneuropathy, and autoimmune hematologic diseases that were nonresponsive to conventional therapies. Proteasome inhibition provides a potent strategy for treating ADs. BTZ represents a proteasome inhibitor that can potentially be used to treat AD patients resistant to conventional therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available